NDUFA11

NADH dehydrogenase [ubiquinone] 1 alpha subco · Q86Y39 · NDUFA11 on Sugi Atlas →

1,349 patent compounds predicted against NDUFA11, 839 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15258558 SCHEMBL15258558 0.76 8/20
SCHEMBL12362713 SCHEMBL12362713 0.77 7/20
SCHEMBL15080621 SCHEMBL15080621 0.77 7/20
SCHEMBL12362702 SCHEMBL12362702 0.73 7/20
SCHEMBL14351066 SCHEMBL14351066 0.69 7/20
SCHEMBL12226742 SCHEMBL12226742 0.61 7/20
SCHEMBL12362734 SCHEMBL12362734 0.60 6/20
SCHEMBL12362700 SCHEMBL12362700 0.57 6/20
SCHEMBL13973668 SCHEMBL13973668 0.47 6/20
SCHEMBL16316892 SCHEMBL16316892 0.47 6/20
Auraptene Auraptene (SCHEMBL2535029) 1.00 5/20
Auraptene Auraptene (SCHEMBL2535034) 1.00 5/20
Umbelliprenin Umbelliprenin (SCHEMBL18265478) 0.98 5/20
SCHEMBL12362712 SCHEMBL12362712 0.80 5/20
SCHEMBL14437596 SCHEMBL14437596 0.57 5/20
SCHEMBL14437626 SCHEMBL14437626 0.57 5/20
SCHEMBL14515244 SCHEMBL14515244 0.57 5/20
SCHEMBL13743063 SCHEMBL13743063 0.43 5/20
SCHEMBL18197750 SCHEMBL18197750 0.41 5/20
SCHEMBL18265492 SCHEMBL18265492 0.74 4/20

Clinical trials — most relevant to NDUFA11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease PHASE3COMPLETED
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) PHASE3WITHDRAWN
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder PHASE2WITHDRAWN
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy PHASE2ACTIVE_NOT_RECRUITING
Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease PHASE2COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) PHASE1/PHASE2NOT_YET_RECRUITING
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)? PHASE1UNKNOWN
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine nanCOMPLETED
The Natural History of Mitochondrial Diseases nanRECRUITING
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) nanRECRUITING
Diagnostic Odyssey Survey 2 nanCOMPLETED
Natural History in Primary Mitochondrial Myopathies nanRECRUITING
Tissue Sample Study for Mitochondrial Disorders nanENROLLING_BY_INVITATION
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes nanNOT_YET_RECRUITING
Nicotinamide Riboside and Mitochondrial Biogenesis nanCOMPLETED
Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection nanCOMPLETED
MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases nanRECRUITING
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip nanCOMPLETED
Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability. nanUNKNOWN
Mitochondrial Dysfunctions Driving Insulin Resistance nanCOMPLETED
Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity nanRECRUITING
GDF-15 as a Biomarker for Mitochondrial Disease nanCOMPLETED
Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders nanCOMPLETED
The International Registry for Leigh Syndrome nanRECRUITING
Ccf mtDNA as a Neurodegenerative Biomarker nanUNKNOWN
Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis nanCOMPLETED
A Study Into the Underlying Biochemical Pathways Involved in Parkinson's Disease, Such as Mitochondrial (Cellular Powerhouse) Dysfunction nanCOMPLETED
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance nanCOMPLETED
Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NDUFA11 binder may also engage these)

ProteinNameSimilarity
Q0MQC0 1.000 Q0MQC0 →
Q0MQB8 1.000 Q0MQB8 →
Q0MQB9 1.000 Q0MQB9 →
Q9D8B4 1.000 Q9D8B4 →
Q8HXG6 0.998 Q8HXG6 →
Q80W89 0.997 Q80W89 →
P25710 0.985 P25710 →
Q9S837 0.983 Q9S837 →
Q54QM0 0.982 Q54QM0 →
O48528 0.982 O48528 →
Q9UUF4 0.979 Q9UUF4 →
Q751T2 0.978 Q751T2 →
P32897 0.977 P32897 →
Q9VN13 0.976 Q9VN13 →
Q9ZV24 0.975 Q9ZV24 →
B6IJ52 0.975 B6IJ52 →
Q6PCS6 0.975 Q6PCS6 →
Q96I45 0.975 Q96I45 →
Q3T0M2 0.974 Q3T0M2 →
Q9N4K0 0.974 Q9N4K0 →
P63030 0.974 P63030 →
Q9HFF0 0.974 Q9HFF0 →
P53721 0.974 P53721 →
Q12029 0.973 Q12029 →
A8E7G5 0.973 A8E7G5 →
O94705 0.973 O94705 →
Q9CRB8 0.973 Q9CRB8 →
Q12328 0.973 Q12328 →
P81928 0.973 P81928 →
Q5RD16 0.973 Q5RD16 →